Targets › TLR4
3 programs from 3 companies in 3 trials: 2 Phase 2, 1 Phase 1; Other, Gastroenterology, Psychiatry; next expected readout Dec 2026.
Transmembrane receptor that functions as a pattern recognition receptor recognizing pathogen- and damage-associated molecular patterns (PAMPs and DAMPs) to induce innate immune responses via downstream signaling pathways. At the plasma membrane, cooperates with LY96 to mediate the innate immune response to bacterial lipopolysaccharide (LPS). (UniProt, O00206)
Open in Phaseline: the race on TLR4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Yaqrit | Resatorvid (TAK-242) Toll-like receptor 4 inhibitor | TLR4 | Phase 2 | Acute-On-Chronic Liver Failure | Aug 2028 |
| Singapore General Hospital | AS01 adjuvant Toll-like receptor agonist; immunological adjuvant containing MPL and QS21 | TLR4 | Phase 2 | Immune System Responses and Trained Immunity After AS01 Administration | Feb 2029 |
| Laureate Institute for Brain Research, Inc. | Lipopolysaccharide (LPS) Toll-like receptor 4 (TLR4) agonist; endotoxin that activates innate immune response | TLR4 | Phase 1 | Major Depressive Disorder | Dec 2026 |
Immune System Responses and Trained Immunity After AS01 Administration (1) Acute-On-Chronic Liver Failure (1) Major Depressive Disorder (1)
protein or peptide (2), mixed (1)
Singapore General Hospital (1) Yaqrit (1) Laureate Institute for Brain Research, Inc. (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.